Challenges and approaches to calibrating patient phenotype as evidence for cancer gene variant classification under ACMG/AMP guidelines

Author:

Fortuno Cristina1ORCID,Michailidou Kyriaki2,Parsons Michael1,Dolinsky Jill S3,Pesaran Tina3,Yussuf Amal3,Mester Jessica L4,Hruska Kathleen S4,Hiraki Susan4,O’Connor Robert5,Chan Raymond C5,Kim Serra5,Tavtigian Sean V6,Goldgar David6,James Paul A78,Spurdle Amanda B19

Affiliation:

1. Population Health Program, QIMR Berghofer Medical Research Institute , Herston, QLD 4006 , Australia

2. Biostatistics Unit, The Cyprus Institute of Neurology and Genetics , Nicosia 2371 , Cyprus

3. Ambry Genetics , Aliso Viejo, CA 92656 , United States

4. GeneDx , Gaithersburg, MD 20877 , United States

5. Color Genomics, Inc. , Burlingame, CA 94010 , United States

6. Huntsman Cancer Institute, University of Utah , Salt Lake City, UT 84112 , United States

7. Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital , Melbourne, VIC 3052 , Australia

8. Sir Peter MacCallum Department of Oncology, University of Melbourne , Melbourne, VIC 3010 , Australia

9. Faculty of Medicine, The University of Queensland , Herston, QLD 4006 , Australia

Abstract

Abstract Since first publication of the American College of Medical Genetics and Genomics/Association for Medical Pathology (ACMG/AMP) variant classification guidelines, additional recommendations for application of certain criteria have been released (https://clinicalgenome.org/docs/), to improve their application in the diagnostic setting. However, none have addressed use of the PS4 and PP4 criteria, capturing patient presentation as evidence towards pathogenicity. Application of PS4 can be done through traditional case–control studies, or “proband counting” within or across clinical testing cohorts. Review of the existing PS4 and PP4 specifications for Hereditary Cancer Gene Variant Curation Expert Panels revealed substantial differences in the approach to defining specifications. Using BRCA1, BRCA2 and TP53 as exemplar genes, we calibrated different methods proposed for applying the “PS4 proband counting” criterion. For each approach, we considered limitations, non-independence with other ACMG/AMP criteria, broader applicability, and variability in results for different datasets. Our findings highlight inherent overlap of proband-counting methods with ACMG/AMP frequency codes, and the importance of calibration to derive dataset-specific code weights that can account for potential between-dataset differences in ascertainment and other factors. Our work emphasizes the advantages and generalizability of logistic regression analysis over simple proband-counting approaches to empirically determine the relative predictive capacity and weight of various personal clinical features in the context of multigene panel testing, for improved variant interpretation. We also provide a general protocol, including instructions for data formatting and a web-server for analysis of personal history parameters, to facilitate dataset-specific calibration analyses required to use such data for germline variant classification.

Funder

NHMRC

National Breast Cancer Foundation

NIH

Publisher

Oxford University Press (OUP)

Subject

Genetics (clinical),Genetics,Molecular Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3